Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H26ClN2O3S2.Na |
Molecular Weight | 537.069 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CN(C)C(=O)CCS[C@H](SCCC([O-])=O)C1=CC(\C=C\C2=NC3=CC(Cl)=CC=C3C=C2)=CC=C1
InChI
InChIKey=XNAYQOBPAXEYLI-LQKFMROPSA-M
InChI=1S/C26H27ClN2O3S2.Na/c1-29(2)24(30)12-14-33-26(34-15-13-25(31)32)20-5-3-4-18(16-20)6-10-22-11-8-19-7-9-21(27)17-23(19)28-22;/h3-11,16-17,26H,12-15H2,1-2H3,(H,31,32);/q;+1/p-1/b10-6+;/t26-;/m1./s1
A potent, selective and orally active receptor antagonist of leukotriene D4, verlukast (MK-571), was discovered and developed from a styrylquinoline lead structure based on a hypothetical model of the leukotriene D4 receptor. MK-571 blocks the action of LTD4 in animals and man, and is effective in a number of animal models of antigen-induced bronchoconstriction at plasma concentration at or below 2 ug/mL. MK-571 also blocks antigen-induced asthmatic responses in man. MK-571 is a potent and selective leukotriene D4 (LTD4) antagonist and ABCC multidrug resistance protein 1(MRP1) inhibitor. The cysteinyl leukotrienes (CysLTs), LTC4, LTD4, and LTE4, mediate their actions through two distinct G-protein coupled receptors. LTD4 is the preferred ligand for the CysLT1 receptor, whereas LTC4 and LTD4 bind with approximately equal affinity to the CysLT2 receptor. MK-571 is a selective, orally active CysLT1 receptor antagonist. It blocks the binding of LTD4, but not LTC4, to human and guinea pig lung membranes with Ki values of 0.22 nM and 2.1 nM, respectively. MK-571 effectively blocks LTD4 activation of recombinant human and mouse CysLT1 receptors but is ineffective at blocking LTC4 or LTD4 activation of the recombinant human or murine CysLT2 receptors.
Originator
Sources: http://adisinsight.springer.com/drugs/800001553 | https://www.ncbi.nlm.nih.gov/pubmed/1793062
Curator's Comment: # Merck & Co
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1798 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2540892 |
2.1 nM [Ki] | ||
Target ID: CHEMBL3004 |
2.8 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. | 1993 Dec |
|
Characterization of the leukotriene D4 receptor in dimethylsulphoxide-differentiated U937 cells: comparison with the leukotriene D4 receptor in human lung and guinea-pig lung. | 1993 Feb 15 |
|
Leukotriene D4-induced increases in cytosolic calcium in THP-1 cells: dependence on extracellular calcium and inhibition with selective leukotriene D4 receptor antagonists. | 1994 Jun |
|
Adenosine triphosphate-dependent transport of anionic conjugates by the rabbit multidrug resistance-associated protein Mrp2 expressed in insect cells. | 1998 Jun |
|
Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells. | 1999 Jan 29 |
|
Characterization of the human cysteinyl leukotriene CysLT1 receptor. | 1999 Jun 24 |
|
Differential sensitivities of MRP1-overexpressing lung tumor cells to cytotoxic metals. | 2000 Jan 3 |
|
Characterization of the human cysteinyl leukotriene 2 receptor. | 2000 Sep 29 |
|
Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. | 2001 Aug |
|
Resistance of human multidrug resistance-associated protein 1-overexpressing lung tumor cells to the anticancer drug arsenic trioxide. | 2001 Jun 1 |
|
Synergistic antiallergic activity of combined histamine H1- and cysteinyl leukotriene1-receptor blockade in human bronchus. | 2001 May 11 |
|
Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors. | 2001 Nov 1 |
|
Functional analysis of ABCA8, a new drug transporter. | 2002 Oct 18 |
|
Leukotrienes mediate murine bronchopulmonary hyperreactivity, inflammation, and part of mucosal metaplasia and tissue injury induced by recombinant murine interleukin-13. | 2003 Apr |
|
Blockage of multidrug resistance-associated proteins potentiates the inhibitory effects of arsenic trioxide on CYP1A1 induction by polycyclic aromatic hydrocarbons. | 2003 Jan |
|
Toxicity of human monocytic THP-1 cells and microglia toward SH-SY5Y neuroblastoma cells is reduced by inhibitors of 5-lipoxygenase and its activating protein FLAP. | 2003 Mar |
|
Leukotrienes mediate part of Ova-induced lung effects in mice via EGFR. | 2003 Oct |
|
The human multidrug-resistance-associated protein MRP1 mediates ATP-dependent transport of unconjugated bilirubin. | 2004 Oct 15 |
|
Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies. | 2004 Sep 25 |
|
Expression and activity of multidrug resistance protein 1 in a murine thymoma cell line. | 2005 Apr |
|
Inhibitory activity of a green tea extract and some of its constituents on multidrug resistance-associated protein 2 functionality. | 2005 Feb |
|
Combined effects of GSTP1 and MRP1 in melanoma drug resistance. | 2005 Jul 25 |
|
Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). | 2005 Sep |
|
Cysteinyl leukotrienes mediate the enhancing effects of indomethacin and aspirin on eosinophil production in murine bone marrow cultures. | 2008 Feb |
|
Multidrug resistance protein transporter and Ins(1,4,5)P₃-sensitive Ca²+-signaling involved in adenosine triphosphate export via Gq protein-coupled NK₂-receptor stimulation with neurokinin A. | 2010 |
|
MRP transporters as membrane machinery in the bradykinin-inducible export of ATP. | 2010 Apr |
|
Differential disposition of chenodeoxycholic acid versus taurocholic acid in response to acute troglitazone exposure in rat hepatocytes. | 2011 Apr |
|
Multidrug resistance-associated protein 1 mediates 15-deoxy-Δ(12,14)-prostaglandin J2-induced expression of glutamate cysteine ligase expression via Nrf2 signaling in human breast cancer cells. | 2011 Aug 15 |
|
Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). | 2013 Dec |
|
The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells. | 2013 Feb 4 |
|
Transcellular transport of aconitine across human intestinal Caco-2 cells. | 2013 Jul |
|
Arsenate accumulation and arsenate-induced glutathione export in astrocyte-rich primary cultures. | 2013 Jun |
|
Multidrug resistance protein 1 (ABCC1) confers resistance to arsenic compounds in human myeloid leukemic HL-60 cells. | 2013 Jun |
|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. | 2013 Nov |
|
Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs. | 2015 Jun |
|
Nrf2 Regulates the Sensitivity of Mouse Keratinocytes to Nitrogen Mustard via Multidrug Resistance-Associated Protein 1 (Mrp1). | 2016 Jan |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8389106
In a three-period, randomized, double-blind, crossover study, single doses of verlukast, 125 and 500 mg, and placebo were given intravenously by bolus infusion to nine patients with moderate, stable asthma (FEV1 40 to 80% predicted) on individual study days separated by a week.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2540892
Verlukast (5.8 x 10(-8)M) antagonized contractions of guinea pig trachea induced by LTC4 in the absence (dose ratio = 28) but not in the presence of 45 mM L-serine borate (dose ratio less than 2). L-660,711 (1.9 x 10(-5)M) did not block contractions of guinea pig trachea induced by histamine, acetylcholine, 5-hydroxytryptamine, PGF2 alpha, U-44069, or PGD2.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Q8W8588793
Created by
admin on Fri Dec 15 15:55:21 GMT 2023 , Edited by admin on Fri Dec 15 15:55:21 GMT 2023
|
PRIMARY | |||
|
162377-77-7
Created by
admin on Fri Dec 15 15:55:21 GMT 2023 , Edited by admin on Fri Dec 15 15:55:21 GMT 2023
|
PRIMARY | |||
|
44322990
Created by
admin on Fri Dec 15 15:55:21 GMT 2023 , Edited by admin on Fri Dec 15 15:55:21 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD